Ajinomoto Co., Inc. (TYO:2802)
Japan · Delayed Price · Currency is JPY | Market Cap | 4.93T +68.5% |
| Revenue (ttm) | 1.58T +3.5% |
| Net Income | 134.68B +91.6% |
| EPS | 138.36 +98.3% |
| Shares Out | 956.83M |
| PE Ratio | 37.24 |
| Forward PE | 36.16 |
| Dividend | 50.00 (0.97%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 9,185,600 |
| Open | 5,140.00 |
| Previous Close | 5,142.00 |
| Day's Range | 5,101.00 - 5,204.00 |
| 52-Week Range | 3,270.00 - 5,739.00 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 5,121.43 (-0.59%) |
| Earnings Date | May 7, 2026 |
About Ajinomoto Co.
Ajinomoto Co., Inc. engages in the seasonings and foods, frozen foods, and healthcare and other businesses in Japan and internationally. The Seasonings and Foods segment offers sauces and seasoning products under the AJI-NO-MOTO, HON-DASHI, Cook Do, Ajinomoto KK Consommé, Pure Select Mayonnaise, Ros Dee, Masako, Aji-ngon, Sazón, Sajiku, and CRISPY FRY names. This segment also provides instant noodles under the Knorr Cup Soup and YumYum names; coffee beverages under the Birdy and Blendy brands; powdered drink under the Birdy 3in1 name; MAXIM bra... [Read more]
Financial Performance
In fiscal year 2026, Ajinomoto Co.'s revenue was 1.58 trillion, an increase of 3.47% compared to the previous year's 1.53 trillion. Earnings were 134.68 billion, an increase of 91.65%.
Financial StatementsNews
Ajinomoto Co. Earnings Call Transcript: Q4 2026
Record sales and business profit were achieved in FY 2025, with strong growth in Healthcare, functional materials, and food products. FY 2026 guidance targets further record highs, while risks from Middle East instability are being managed through flexible cost and supply strategies.
Ajinomoto Co. Slides: Q4 2026
Ajinomoto Co. has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.
Ajinomoto Co. Quarterly report: Q4 2026
Ajinomoto Co. has published its Q4 2026 quarterly earnings report on May 7, 2026.
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing
Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to c...
Is MSG Maker Ajinomoto Sitting on an AI Goldmine? This Investor Thinks So
An activist investor has built a stake in a Japanese company it says has a lucrative monopoly on a material vital to artificial-intelligence infrastructure.
Ajinomoto Co. Transcript: Investor update
Governance and compliance frameworks were strengthened, with a revised code of conduct and new compliance committee. Executive compensation is being restructured to better align with performance and shareholder value, while portfolio and audit practices emphasize transparency and risk management.
Ajinomoto Co. Slides: Investor update
Ajinomoto Co. has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Palliser Capital Publishes Value Enhancement Plan for Ajinomoto
LONDON--(BUSINESS WIRE)--Palliser Capital (“Palliser”), a top 25 shareholder of Ajinomoto Co., Inc. (“Ajinomoto” or the “Company”), today published a comprehensive presentation outlining the opportuni...
Ajinomoto Co. Transcript: Investor Day 2026
Sustainability is central to strategy, with a focus on agri-food system transformation, health, and nutrition. Key innovations like biostimulants and AjiPro-L target both environmental and business growth, supported by partnerships and financial schemes. Sales targets for these solutions are set to double by 2030.
Ajinomoto Co. Slides: FY 2026
Ajinomoto Co. has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 15, 2026.
Ajinomoto Co. Earnings Call Transcript: Q3 2026
Record highs in sales and profit were achieved in Q3 FY2025, driven by strong growth in Seasonings, Foods, and Functional Materials. Upward revisions were made to full-year profit forecasts, with robust performance expected to continue, supported by asset sales and margin improvements.
Ajinomoto Co. Quarterly report: Q3 2026
Ajinomoto Co. has published its Q3 2026 quarterly earnings report on February 5, 2026.
Ajinomoto Co. Slides: Q3 2026
Ajinomoto Co. has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 5, 2026.
Ajinomoto Co. Earnings Call Transcript: Q2 2026
First half FY2025 results were flat year-over-year, with profit growth in healthcare and others offset by declines in frozen foods and umami seasonings. Management expects a strong recovery in the second half, supported by strategic actions, new technologies, and continued investment in innovation.
Ajinomoto Co. Quarterly report: Q2 2026
Ajinomoto Co. has published its Q2 2026 quarterly earnings report on November 6, 2025.
Ajinomoto Co. Slides: Q2 2026
Ajinomoto Co. has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.
Ajinomoto Co. Transcript: Investor Update
Latin American operations are expanding with strong market shares, robust distribution, and new product launches in food and bio-fine chemicals. Sustainability initiatives like the Biocycle and Agipro L are central, with a focus on GHG reduction and digital transformation. Growth is supported by innovation, human capital, and adaptation to evolving consumer needs.
Ajinomoto Co. Slides: Investor Update
Ajinomoto Co. has posted slides in relation to its latest quarterly earnings report, which was published on October 13, 2025.
Ajinomoto Co. Earnings Call Transcript: Q1 2026
Organic sales grew 3% year-on-year, with business profit up 12% and profit margin at 13%. Strong gains in Functional Materials and Bio-Pharma offset challenges in Japan's frozen foods, while currency and raw material costs remain key risks.
Ajinomoto Co. Quarterly report: Q1 2026
Ajinomoto Co. has published its Q1 2026 quarterly earnings report on August 4, 2025.
Ajinomoto Co. Slides: Q1 2026
Ajinomoto Co. has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 4, 2025.
Ajinomoto Co. Transcript: Investor update
Plans to double medical food sales by FY2030 focus on innovation, global expansion, and leveraging amino science. Cambrooke and Nualtra drive growth through strong patient and practitioner relationships, rapid product development, and high-margin segments, outpacing market growth.
Ajinomoto Co. Slides: Investor update
Ajinomoto Co. has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2025.
Ajinomoto Co. Earnings Call Transcript: Q4 2025
Record FY2024 sales and business profit were achieved, despite one-time costs from structural reforms. FY2025 is forecasted to deliver further growth, with strong performance expected in seasonings, foods, and functional materials, and a major share buyback announced.
Ajinomoto Co. Quarterly report: Q4 2025
Ajinomoto Co. has published its Q4 2025 quarterly earnings report on May 8, 2025.